ClinicalTrials.gg
RecruitingNCT07033689Updated Apr 3, 2026

Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)

An Early Phase 1 interventional study of Suizenji (an ultrasound-guided HIFU therapy system) and Nal-IRI/FL in Pancreatic Cancer, sponsored by SONIRE Therapeutics Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by SONIRE Therapeutics Inc. · Early Phase 1, Interventional, and Device feasibility

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing irinotecan sucrosofate in Pancreatic Neoplasms — 10 open to participants now, 12 under way, none of them phase 3. irinotecan sucrosofate · Pancreatic Neoplasms.

Planned enrollment
23rd of 23
10 · median 64
Started
2026
the only one that year
Phase 1
4 of 23
1 open now
Primary completion
2026-12
later than 8 of 11 live
Registered
23rd of 23
by date

Among the 23 studies testing irinotecan sucrosofate in Pancreatic Neoplasms, this one is the 23rd largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 1, reaches primary completion later than 8 of the 11 other live ones, and was the 23rd registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

10 of the 23 studies testing irinotecan sucrosofate in Pancreatic Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About irinotecan sucrosofate

irinotecan sucrosofate: first FDA approval 2015 (ONIVYDE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing irinotecan sucrosofate in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

This is a feasibility, safety, tolerability, and efficacy research study of an investigational device called "Suizenji", an ultrasound-guided high-intensity focused ultrasound (HIFU) therapy system for the treatment of unresectable pancreatic ductal adenocarcinoma. Focused ultrasound therapy uses a number of small ultrasound generators attached to a bowl-shaped ultrasound generator to emit ultrasound waves from outside to inside the body and focus them on a single point where cancerous cells in the pancreas are located. The targeted area is then heated, which kills the pancreatic cancer cells, and as a result, the patient's life may be prolonged. Experience with Suizenji for pancreatic cancer patients has shown that the "heating" is only a warm feeling in the abdomen during the treatment.

Read the detailed description

Study Title An Open-label, Non-randomized, Single-center Study Investigating the Feasibility, Safety, Tolerability and Efficacy of Suizenji, an Ultrasound-guided HIFU Therapy System, in Patients with Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II) Objectives Primary objectives

  1. To evaluate the safety and tolerability of Suizenji. Secondary objectives
  2. To evaluate the overall performance of Suizenji.
  3. To explore technical success and preliminary clinical efficacy of Suizenji. Trial Stages Feasibility study Investigational site Stanford Cancer Institute Study Design This is an open-label, non-randomized, single-center study.

The study will consist of:

  • A screening period
  • HIFU treatment procedure(s) and post-HIFU assessments
  • Initiation of 1st line chemotherapy
  • Follow-up visits at Month 1 and Month 3
  • Long-term follow-up visits until death or up to 5 years Subjects will sign a consent form prior to any study related procedure and will complete baseline screening assessments.

All eligible subjects will be enrolled in the study and will receive HIFU treatment on Day 1. An additional session will be required prior to the initiation of chemotherapy if one of the following; (1) ablation is not completed as planned, or (2) insufficiently ablated per PI's discretion.

After the post HIFU assessment is completed, standard 1st line chemotherapy (FOLFIRINOX (or modified FOLFIRINOX), Gem/nab-PTX, or NALIRIFOX) will be started. The interval from enrollment and the initiation of chemotherapy will be within 2 weeks. All HIFU treatment(s) and post HIFU assessment need to be completed during this 2-week interval.

Subjects will come back for follow-up visits at Month 1 and Month 3. After 3 subjects have completed the one-month evaluation, the DSMB will review the safety and efficacy (except immune response) data up to the Month 1 visit to recommend if the study can continue or if a protocol amendment will be required.

Total 10 subjects are planned to be enrolled. Duration of Subject Participation Subjects will be in the study for up to 3.5 months+ additional long-term follow-up until death or up to 5 years.

Screening: up to 7 days Treatment: 1 day for 1 session + additional sessions if required Follow-up: 3 months Long-term follow-up: until death or up to 5 years Study Population Subjects with unresectable locally advanced or metastatic PDAC.

Inclusion criteria

  1. Signed an Institutional Review Board (IRB) approved informed consent document.
  2. Men and women ≥ 22 years of age.
  3. Histologically or cytologically diagnosed PDAC.
  4. Newly diagnosed unresectable*, locally advanced or metastatic disease.
  5. Primary tumor accessible to HIFU treatment and visualized on transabdominal ultrasonography.
  6. Primary tumor site must be a measurable lesion according to RECIST version 1.1 at baseline.
  7. ECOG Performance Status (ECOG-PS) of 0 - 1.
  8. Life expectancy ≥ 3 months.
  9. Adequate organ function defined by:

    • Neutrophil count: ≥ 1,500/mm3
    • Platelet count: ≥ 50,000/mm3
    • Hemoglobin: ≥ 8.0 g/dl
    • Cr: ≤ 1.7 mg/dl
    • AST, ALT: ≤ 3 x upper limit of normal
    • T-Bil: ≤ 2 x upper limit of normal

Exclusion criteria

  1. Subjects with any cancers other than PDAC who are on active treatment.
  2. Subjects who had any prior chemotherapy or interventions for PDAC.
  3. Obstructive jaundice (except for subjects who have a bile duct stent placed for obstructive jaundice prior to initiation of HIFU treatment).
  4. Tumor embolization in the veins surrounding the pancreas.
  5. Cysts outside of primary pancreatic tumor which may obstruct the HIFU sonication pathway. However, if the cyst is completely surrounded by pancreatic tumor, the subject can be included.
  6. Subjects with > 50% reduction in caliber of the principal hepatic artery and occlusion of the portal vein seen on preoperative screening CT or MRI scan.
  7. Allergy to contrast agents (except when manageable by prophylactic steroid).
  8. Subjects having a cardiac pacemaker.
  9. Congestive heart failure, symptomatic coronary artery disease, arrhythmia poorly controlled by drugs, history of myocardial infarction or unstable angina within the past 6 months.
  10. Subjects with peritoneal dissemination.
  11. Active infections requiring systemic treatment.
  12. Pregnancy or women of childbearing potential not willing to follow the birth control as described in the informed consent and/or who are breastfeeding.
  13. Received unapproved or investigational drug or device within 30 days of the subject's study start date.
  14. The judgment of the investigator would make the subject inappropriate for entry into the study.

Device Suizenji (an ultrasound-guided HIFU therapy system) HIFU Treatment Treatment will sonicate at least 50% of the tumor volume. Safety margins between the sonication focus (Red box on the Suizenji screen) to adjacent critical structures such as the bowel and blood vessels will be 10 mm in the anterior-posterior direction and 5 mm in the medial-lateral direction. Subjects will receive the 1st session of HIFU treatment on Day 1. An additional session will be required prior to the initiation of chemotherapy if one of the following; (1) ablation is not completed as planned, or (2) insufficiently ablated per PI's discretion.

If at any time during the treatment procedure, a subject uses the "stop button" indicating pain or discomfort, HIFU treatment will immediately be paused. It will resume only after the subject's pain or discomfort has resolved and the subject is ready to continue. If the subject does not wish to continue on that day, this session can be rescheduled for another day. All HIFU treatment sessions need to be completed prior to the start of chemotherapy.

If any of the following conditions are observed on the day of HIFU treatment, HIFU treatment will be paused until complete resolution:

  • Fever exceeding 38°C;
  • Impaired consciousness;
  • Shock symptoms with systolic blood pressure below 90 mmHg, cold sweat and pallor;
  • Jaundice (as judged by the investigators);
  • Severe neutropenia, thrombocytopenia, abnormal liver function (increased AST, ALT), abnormal renal function (increased serum creatinine), or increased serum amylase in the most recent clinical examination (severe is defined as Grade 3 or higher in NCI-CTCAE ver. 5.0);
  • or any other conditions per investigator's discretion which may not be in the subject's best interest to continue in the study.

If these conditions are not resolved within the HIFU treatment window (prior to initiate the chemotherapy), the subject will be withdrawn the study.

Concomitant and Prohibited medication Standard 1st line chemotherapy FOLFIRINOX (or modified FOLFIRINOX), Gem/nab-PTX, or NALIRIFOX Prohibited previous medications

  • Any treatment for pancreatic cancer.
  • Investigational medications or investigational medical device within 30 days of the HIFU treatment.

Prohibited concomitant medications (up to 3 months visit)

  • Any systemic or local treatment such as immunotherapies, radiotherapy, other adjunctive oncologic treatments to the primary lesion of pancreas as well as to the metastatic lesions.
  • Investigational medications or investigational medical device. Safety Assessments Safety and tolerability assessments

    1) Procedure limiting toxicities (up to 30 days post last HIFU treatment)

  • Bowel perforation ≥ Grade 3;
  • Any other toxicities > Grade 3 with the exception of:

    • Grade 3 abdominal pain unless new and persistent (> 2 weeks duration post HIFU) despite maximal supportive care measures as prescribed by the treating physician;
    • Grade 3 pancreatic duct stenosis, unless new and persistent (> 2 weeks duration post HIFU) despite maximal supportive care measures as prescribed by the treating physician;
    • Grade 3 bile duct stenosis, unless new and persistent (> 2 weeks duration post HIFU) despite maximal supportive care measures as prescribed by the treating physician;
    • Grade 3 fever;
    • Grade 3 pain unless new and persistent (> 2 weeks duration post HIFU) despite maximal supportive care measures as prescribed by the treating physician;
    • Grade 3 increase in lipase or amylase. 2) Adverse events 3) Expected procedure-related local AEs by CTCAE (up to 30 days post last HIFU treatment)
  • Pain during and immediately after the HIFU treatment
  • Skin redness
  • Skin burning 4) Other safety assessments
  • Safety lab (hematology, blood chemistry, coagulation, and urinalysis)
  • ECG
  • Vital Signs/weight
  • ECOG-PS
  • Numerical Rating Scale (NRS) and analgesics use for abdominal pain Technical Success Assessments In this proposed feasibility study, various options of imaging modalities such as pre- and post-contrast-enhanced CT/MRI, PET-CT and contrast enhanced ultrasonography, and fine needle biopsy will be explored in actual clinical setting (PDAC patients).

Technical success of the HIFU ablation defined as > 50% of treated volume assessed by MRI and/or contrast-enhanced CT after the last HIFU.

In this study, the ablation volume will be assessed post HIFU by the change in volume of hypointensity on non-contrast T1 MRI and by the non-perfused volume (NPV) on contrast-enhanced CT/MRI primary. In addition, other MRI sequences, PET-CT, contrast enhanced ultrasonography, histopathological change data may be collected for exploratory ablation assessment.

Other Assessments Clinical Efficacy Endpoints

  • Overall Response Rate up to Month 3 visit
  • Change of Tumor volume at primary lesion
  • Disease Control Rate
  • Tumor Marker (CA19-9, CEA)
  • FDG-PET (change from the baseline)
  • Immune responses (Tissue, Peripheral blood)
  • Numerical Rating Scale (NRS) and analgesics use for abdominal pain
  • Long-term oncological outcomes (Progression Free Survival and Overall Survival) Procedure Feasibility Endpoints
  • Completion rate of HIFU treatment procedure Study Premature Termination or Study Suspension Criteria If any of the following events occur, the study will be suspended pending DSMB review.
  • Any SAE associated with HIFU treatment.
  • Any procedure limited toxicities (up to 30 days post last HIFU treatment).
  • Any > Grade 3 toxicity associated with HIFU treatment.
  • Any death that occurs within 30 days of receiving HIFU treatment.

Either the Sponsor or the PI reserve the right to temporarily suspend or prematurely terminate the study at any time if there is sufficient reasonable cause.

Written notification, documenting the reason for study suspension or termination, will be provided by the suspending or terminating party to the PI, Sponsor, and FDA.

If the study is prematurely terminated or suspended, the PI will promptly inform the IRB and will provide the reason(s) for the termination or suspension.

Circumstances that may warrant termination or suspension, include, but are not limited to:

  • Determination of unexpected, significant, or unacceptable risk to subjects
  • Insufficient compliance to protocol requirements
  • Data that are not sufficiently complete and/or evaluable The study may resume once concerns about safety, protocol compliance and data quality have been addressed and satisfied by the Sponsor, IRB, and FDA DSMB The membership includes three clinicians (medical oncologist, surgical oncologist, and gastroenterologist) specializing in pancreatic cancer treatment and the medical monitor.

Sample Size Total 10 subjects will be treated.

03

Conditions studied

  • Pancreatic Cancer

Keywords

  • Pancreatic Cancer,
  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Signed an Institutional Review Board (IRB) approved document.
  2. Men and women ≥ 18 years of age.
  3. or cytologically diagnosed PDAC.
  4. Newly diagnosed unresectable*, locally advanced or disease. (* defined as not "Resectable" and not "borderline resectable" based on "Criteria Defining Resectability at Diagnosis" in NCCN Guideline 2024)
  5. Primary tumor accessible to HIFU treatment and visualized on transabdominal ultrasonography.
  6. Primary tumor site must be a according to version 1.1 at baseline.
  7. Performance Status (ECOG-PS) of 0 - 1.
  8. ≥ 3 months.
  9. Adequate organ function defined by:

    • : ≥ 1,500/mm3
    • count: ≥ 50,000/mm3
    • : ≥ 8.0 g/dl
    • Cr: ≤ 1.7 mg/dl
    • , ALT: ≤ 3 x
    • T-Bil: ≤ 2 x upper limit of normal

Exclusion Criteria:

  1. Subjects with any cancers other than PDAC who are on active treatment.
  2. Subjects who had any prior chemotherapy or interventions for PDAC.
  3. Obstructive jaundice (except for subjects who have a bile duct stent placed for obstructive jaundice prior to initiation of HIFU treatment).
  4. Tumor embolization in the veins surrounding the pancreas.
  5. Cysts outside of primary pancreatic tumor which may obstruct the HIFU sonication pathway. However, if the cyst is completely surrounded by pancreatic tumor, the subject can be included.
  6. Subjects with > 50% reduction in caliber of the principal hepatic artery and occlusion of the portal vein seen on preoperative screening CT or MRI scan.
  7. Allergy to contrast agents (except when manageable by prophylactic ).
  8. Subjects having a cardiac pacemaker.
  9. Congestive heart failure, symptomatic coronary artery disease, arrhythmia poorly controlled by drugs, history of myocardial infarction or unstable angina within the past 6 months.
  10. Subjects with peritoneal dissemination.
  11. Active infections requiring systemic treatment.
  12. Pregnancy or women of not willing to follow the as described in the informed consent and/or who are breastfeeding.
  13. Received unapproved or drug or device within 30 days of the subject's study start date.
  14. The judgment of the investigator would make the subject inappropriate for entry into the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Suizenji (an ultrasound-guided HIFU therapy system)

    Suizenji (an ultrasound-guided HIFU therapy system)

    Device: Suizenji (an ultrasound-guided HIFU therapy system) · Drug: Nal-IRI/FL · Drug: mFOLFIRINOX adjuvant chemotherapy · Drug: Gem/nab-PTX

Interventions

  • DeviceSuizenji (an ultrasound-guided HIFU therapy system)

    Suizenji (an ultrasound-guided HIFU therapy system)

    Also known as: ultrasound-guided HIFU therapy system

  • DrugNal-IRI/FL

    Drug page: Irinotecan sucrosofate

    Standard of care

  • DrugmFOLFIRINOX adjuvant chemotherapy

    standard of care

  • DrugGem/nab-PTX

    standard of care

06

What researchers measure

Primary outcomes

  1. Technical success for device feasibility

    Technical success of the HIFU ablation defined as \> 50% of treated volume assessed by MRI and/or contrast-enhanced CT after the last HIFU. Change from Baseline.

    Time frame: 3 Months

Secondary outcomes

  1. Clinical Efficacy

    Overall Response Rate from baseline up to Month 3 visit

    Time frame: 3 Months

  2. Tumor volume

    Change of Tumor volume at primary lesion from baseline to month 3

    Time frame: 3 Months

  3. Disease Control Rate

    Rate of disease spread from baseline to month 3

    Time frame: 3 months

  4. Tumor Marker

    Tumor Marker change from baseline to month 3

    Time frame: 3 months

  5. FDG-PET

    FDG-PET change from the baseline to Month 3

    Time frame: 3 months

  6. Immune responses

    Change from baseline in Immune responses

    Time frame: 3 months

  7. Numerical Rating Scale (NRS)

    Numerical Rating Scale (NRS) and analgesics use for abdominal pain from baseline to Month 3

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Stanford University
    San Francisco, California 94305, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Increase be treatment options for this patient population

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.

Of 171 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's planned 10 months is below that.

Counting every sponsor, half of 379 studies reached it within 45 months; a quarter within 32 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 24, 2025
StartActual
Jan 5, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Mar 1, 2027
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07033689
Lead sponsor
SONIRE Therapeutics Inc.
Responsible party
Sponsor
First posted
Jun 24, 2025
Start date
Jan 5, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Apr 3, 2026

Study contacts

Minako Koga
Contact
mkoga@kmphc.com
202-615-6004
Pejman Ghanouni, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irinotecan sucrosofate

Start the discussion